SPX4,145.19
0.16%Negative
IXIC12,657.56
0.50%Negative
DJI32,803.47
0.23%Positive
STOXX435.72
0.76%Negative
FTSE7,439.74
0.11%Negative
N22528,175.87
0.87%Positive

Avenue Therapeutics Inc

ATXI.OQ

Official Data Partner

Latest Trade: trading lower0.27USD
Change: -0.01
% Change: 1.93%Negative

As of Aug 7 2022. Values delayed up to 15 minutes

Day Range: 0.26 - 0.28
52-Week Range: 0.20 - 1.88

Previous Close: 0.28
Open: 0.28
Volume: 12,816.00
3 Month Average Trading Volume: 5.55
Shares Out (Mil): 22.13
Market Cap: 5.94
Forward P/E: -99,999.99
Dividend Yield: -99,999.99

Key Statistics

mean rating - analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): -99,999.99
Price To Sales (TTM): -99,999.99
Price To Book (Quarterly): 5.22
Price To Cash Flow (Per Share TTM): -99,999.99
Total Debt/Total Equity (Quarterly): 0.00
Long Term Debt/Equity (Quarterly): 0.00
Return On Investment (TTM): -424.75
Return On Equity (TTM): -286.87

2021 (millions USD)

About Avenue Therapeutics Inc (ATXI.OQ)

Company Information

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing and commercializing its product principally for use in the acute/intensive care hospital setting. It is focused on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV) Tramadol, for post-operative acute pain. Tramadol, is a synthetic dual-acting opioid, a centrally acting analgesic with opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. The opioid and non-opioid modes of action are synergistic, providing multimodal therapy with the use of a single drug. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet.